Buchumschlag

Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial

Background - Non-clear cell renal cell cancers (nccRCCs) are a heterogeneous group of more than 20 different entities, but are rarely included in large, randomized trials. Tyrosine kinase inhibitors with or without immune checkpoint inhibition are considered as a standard of care (SOC), but optimal...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bergmann, Lothar (VerfasserIn) , Albiges, L. (VerfasserIn) , Ahrens, M. (VerfasserIn) , Gross-Goupil, M. (VerfasserIn) , Boleti, E. (VerfasserIn) , Gravis, G. (VerfasserIn) , Fléchon, A. (VerfasserIn) , Grimm, M. -O. (VerfasserIn) , Bedke, J. (VerfasserIn) , Barthélémy, P. (VerfasserIn) , Castellano, D. (VerfasserIn) , Mellado, B. (VerfasserIn) , Ivanyi, P. (VerfasserIn) , Rottey, S. (VerfasserIn) , Flörcken, A. (VerfasserIn) , Suarez, C. (VerfasserIn) , Maroto, P. (VerfasserIn) , Grünwald, V. (VerfasserIn) , Oosting, S. F. (VerfasserIn) , Kopecky, J. (VerfasserIn) , Zschäbitz, Stefanie (VerfasserIn) , Boegemann, M. (VerfasserIn) , Buchler, T. (VerfasserIn) , Niegisch, G. (VerfasserIn) , Goebell, P. J. (VerfasserIn) , Waddell, T. (VerfasserIn) , Joly, F. (VerfasserIn) , Priou, F. (VerfasserIn) , Retz, M. (VerfasserIn) , Siemer, S. (VerfasserIn) , Zimmermann, U. (VerfasserIn) , Deckbar, D. (VerfasserIn) , Burkholder, I. (VerfasserIn) , Hartmann, A. (VerfasserIn) , Haanen, J. B. (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: July 2025
In: Annals of oncology
Year: 2025, Jahrgang: 36, Heft: 7, Pages: 796-806
ISSN:1569-8041
DOI:10.1016/j.annonc.2025.03.016
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.annonc.2025.03.016
Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S0923753425001243
Volltext
Verfasserangaben:L. Bergmann, L. Albiges, M. Ahrens, M. Gross-Goupil, E. Boleti, G. Gravis, A. Fléchon, M.-O. Grimm, J. Bedke, P. Barthélémy, D. Castellano, B. Mellado, P. Ivanyi, S. Rottey, A. Flörcken, C. Suarez, P. Maroto, V. Grünwald, S.F. Oosting, J. Kopecky, S. Zschäbitz, M. Boegemann, T. Buchler, G. Niegisch, P.J. Goebell, T. Waddell, F. Joly, F. Priou, M. Retz, S. Siemer, U. Zimmermann, D. Deckbar, I. Burkholder, A. Hartmann & J.B. Haanen, Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN)

MARC

LEADER 00000naa a2200000 c 4500
001 1942753071
003 DE-627
005 20251128095423.0
007 cr uuu---uuuuu
008 251128s2025 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.annonc.2025.03.016  |2 doi 
035 |a (DE-627)1942753071 
035 |a (DE-599)KXP1942753071 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Bergmann, Lothar  |d 1949-  |e VerfasserIn  |0 (DE-588)1033494933  |0 (DE-627)741316471  |0 (DE-576)381105695  |4 aut 
245 1 0 |a Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial  |c L. Bergmann, L. Albiges, M. Ahrens, M. Gross-Goupil, E. Boleti, G. Gravis, A. Fléchon, M.-O. Grimm, J. Bedke, P. Barthélémy, D. Castellano, B. Mellado, P. Ivanyi, S. Rottey, A. Flörcken, C. Suarez, P. Maroto, V. Grünwald, S.F. Oosting, J. Kopecky, S. Zschäbitz, M. Boegemann, T. Buchler, G. Niegisch, P.J. Goebell, T. Waddell, F. Joly, F. Priou, M. Retz, S. Siemer, U. Zimmermann, D. Deckbar, I. Burkholder, A. Hartmann & J.B. Haanen, Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN) 
264 1 |c July 2025 
300 |b Illustrationen 
300 |a 11 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Online verfügbar: 1. April 2025, Artikelversion: 13. Juni 2025 
500 |a Gesehen am 28.11.2025 
520 |a Background - Non-clear cell renal cell cancers (nccRCCs) are a heterogeneous group of more than 20 different entities, but are rarely included in large, randomized trials. Tyrosine kinase inhibitors with or without immune checkpoint inhibition are considered as a standard of care (SOC), but optimal treatment is not yet defined. We designed the first prospective randomized trial comparing ipilimumab/nivolumab to SOC. - Patients and methods - We randomized adult patients with previously untreated advanced or metastatic nccRCC 1:1 to nivolumab 3 mg/kg plus ipilimumab 1 mg/kg every 3 weeks for 4 doses followed by fixed dose nivolumab of 240 mg every 2 weeks or 480 mg every 4 weeks or to SOC. Patients were stratified by histology and by IMDC risk score. Central pathology review was mandatory. The primary endpoint was the overall survival (OS) rate at 12 months, secondary endpoints included median OS, response rate, progression-free survival (PFS), safety and quality of life. - Results - In total, 157 patients were assigned to receive ipilimumab/nivolumab, and 152 to SOC. The 12-month survival rate was 78% with ipilimumab/nivolumab [95% confidence interval (CI) 71-84%] compared to 68% with SOC (95% CI 60-75%, P = 0.026). Median OS was 33.2 months versus 25.2 months, P = 0.163 [HR 0.81 (0.61-1.099)]. PFS was similar in both arms [HR 0.99 (0.77-1.28)]. The ORR was 32.8% versus 19.3%. No major differences between papillary and non-papillary RCC subtypes were observed for any endpoint. Exploratory analysis showed a significant OS advantage [HR 0.56 (95% CI 0.37-0.86)] associated with a PD-L1 CPS score ≥1. Treatment discontinuation due to toxicity occurred in 27 patients (17%) with ipilimumab/nivolumab and 13 patients (9%) with SOC. - Conclusions - Ipilimumab/nivolumab demonstrated a significantly longer OS at the 12-month milestone and an acceptable toxicity profile. Our results therefore underline a relevant clinical benefit of ipilimumab/nivolumab in previously untreated nccRCC entities compared to current SOC. 
650 4 |a checkpoint inhibitors 
650 4 |a ipilimumab 
650 4 |a nccRCC 
650 4 |a nivolumab 
650 4 |a non-clear cell renal cell carcinoma 
650 4 |a tyrosine kinase inhibitors 
700 1 |a Albiges, L.  |e VerfasserIn  |4 aut 
700 1 |a Ahrens, M.  |e VerfasserIn  |4 aut 
700 1 |a Gross-Goupil, M.  |e VerfasserIn  |4 aut 
700 1 |a Boleti, E.  |e VerfasserIn  |4 aut 
700 1 |a Gravis, G.  |e VerfasserIn  |4 aut 
700 1 |a Fléchon, A.  |e VerfasserIn  |4 aut 
700 1 |a Grimm, M. -O.  |e VerfasserIn  |4 aut 
700 1 |a Bedke, J.  |e VerfasserIn  |4 aut 
700 1 |a Barthélémy, P.  |e VerfasserIn  |4 aut 
700 1 |a Castellano, D.  |e VerfasserIn  |4 aut 
700 1 |a Mellado, B.  |e VerfasserIn  |4 aut 
700 1 |a Ivanyi, P.  |e VerfasserIn  |4 aut 
700 1 |a Rottey, S.  |e VerfasserIn  |4 aut 
700 1 |a Flörcken, A.  |e VerfasserIn  |4 aut 
700 1 |a Suarez, C.  |e VerfasserIn  |4 aut 
700 1 |a Maroto, P.  |e VerfasserIn  |4 aut 
700 1 |a Grünwald, V.  |e VerfasserIn  |4 aut 
700 1 |a Oosting, S. F.  |e VerfasserIn  |4 aut 
700 1 |a Kopecky, J.  |e VerfasserIn  |4 aut 
700 1 |a Zschäbitz, Stefanie  |d 1983-  |e VerfasserIn  |0 (DE-588)1037698827  |0 (DE-627)75589894X  |0 (DE-576)391727206  |4 aut 
700 1 |a Boegemann, M.  |e VerfasserIn  |4 aut 
700 1 |a Buchler, T.  |e VerfasserIn  |4 aut 
700 1 |a Niegisch, G.  |e VerfasserIn  |4 aut 
700 1 |a Goebell, P. J.  |e VerfasserIn  |4 aut 
700 1 |a Waddell, T.  |e VerfasserIn  |4 aut 
700 1 |a Joly, F.  |e VerfasserIn  |4 aut 
700 1 |a Priou, F.  |e VerfasserIn  |4 aut 
700 1 |a Retz, M.  |e VerfasserIn  |4 aut 
700 1 |a Siemer, S.  |e VerfasserIn  |4 aut 
700 1 |a Zimmermann, U.  |e VerfasserIn  |4 aut 
700 1 |a Deckbar, D.  |e VerfasserIn  |4 aut 
700 1 |a Burkholder, I.  |e VerfasserIn  |4 aut 
700 1 |a Hartmann, A.  |e VerfasserIn  |4 aut 
700 1 |a Haanen, J. B.  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Annals of oncology  |d Amsterdam [u.a.] : Elsevier, 1990  |g 36(2025), 7 vom: Juli, Seite 796-806  |h Online-Ressource  |w (DE-627)320428796  |w (DE-600)2003498-2  |w (DE-576)098134345  |x 1569-8041  |7 nnas  |a Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial 
773 1 8 |g volume:36  |g year:2025  |g number:7  |g month:07  |g pages:796-806  |g extent:11  |a Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial 
856 4 0 |u https://doi.org/10.1016/j.annonc.2025.03.016  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext 
856 4 0 |u https://www.sciencedirect.com/science/article/pii/S0923753425001243  |x Verlag  |z kostenfrei  |3 Volltext 
951 |a AR 
992 |a 20251128 
993 |a Article 
994 |a 2025 
998 |g 1037698827  |a Zschäbitz, Stefanie  |m 1037698827:Zschäbitz, Stefanie  |d 910000  |d 910100  |d 50000  |e 910000PZ1037698827  |e 910100PZ1037698827  |e 50000PZ1037698827  |k 0/910000/  |k 1/910000/910100/  |k 0/50000/  |p 21 
999 |a KXP-PPN1942753071  |e 4815421684 
BIB |a Y 
SER |a journal 
JSO |a {"note":["Online verfügbar: 1. April 2025, Artikelversion: 13. Juni 2025","Gesehen am 28.11.2025"],"relHost":[{"corporate":[{"display":"European Society for Medical Oncology","role":"isb"}],"origin":[{"dateIssuedKey":"1990","publisherPlace":"Amsterdam [u.a.] ; Dordrecht [u.a.] ; Oxford","publisher":"Elsevier ; Kluwer ; Oxford Univ. Press","dateIssuedDisp":"1990-"}],"title":[{"title":"Annals of oncology","subtitle":"official journal of the European Society for Medical Oncology","title_sort":"Annals of oncology"}],"part":{"year":"2025","pages":"796-806","volume":"36","text":"36(2025), 7 vom: Juli, Seite 796-806","extent":"11","issue":"7"},"id":{"eki":["320428796"],"zdb":["2003498-2"],"issn":["1569-8041"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 12.11.20","Ungezählte Beil.: Supplement"],"recId":"320428796","disp":"Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trialAnnals of oncology","language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.1990 -"]}],"physDesc":[{"noteIll":"Illustrationen","extent":"11 S."}],"id":{"doi":["10.1016/j.annonc.2025.03.016"],"eki":["1942753071"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"title":[{"title":"Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial","title_sort":"Prospective randomized phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer - results of the SUNNIFORECAST trial"}],"language":["eng"],"person":[{"role":"aut","family":"Bergmann","given":"Lothar","display":"Bergmann, Lothar"},{"family":"Albiges","display":"Albiges, L.","given":"L.","role":"aut"},{"role":"aut","display":"Ahrens, M.","given":"M.","family":"Ahrens"},{"role":"aut","given":"M.","display":"Gross-Goupil, M.","family":"Gross-Goupil"},{"role":"aut","family":"Boleti","display":"Boleti, E.","given":"E."},{"family":"Gravis","display":"Gravis, G.","given":"G.","role":"aut"},{"role":"aut","family":"Fléchon","display":"Fléchon, A.","given":"A."},{"display":"Grimm, M. -O.","given":"M. -O.","family":"Grimm","role":"aut"},{"display":"Bedke, J.","given":"J.","family":"Bedke","role":"aut"},{"given":"P.","display":"Barthélémy, P.","family":"Barthélémy","role":"aut"},{"display":"Castellano, D.","given":"D.","family":"Castellano","role":"aut"},{"role":"aut","given":"B.","display":"Mellado, B.","family":"Mellado"},{"given":"P.","display":"Ivanyi, P.","family":"Ivanyi","role":"aut"},{"role":"aut","family":"Rottey","display":"Rottey, S.","given":"S."},{"role":"aut","family":"Flörcken","display":"Flörcken, A.","given":"A."},{"family":"Suarez","given":"C.","display":"Suarez, C.","role":"aut"},{"display":"Maroto, P.","given":"P.","family":"Maroto","role":"aut"},{"given":"V.","display":"Grünwald, V.","family":"Grünwald","role":"aut"},{"display":"Oosting, S. F.","given":"S. F.","family":"Oosting","role":"aut"},{"role":"aut","given":"J.","display":"Kopecky, J.","family":"Kopecky"},{"role":"aut","display":"Zschäbitz, Stefanie","given":"Stefanie","family":"Zschäbitz"},{"role":"aut","family":"Boegemann","display":"Boegemann, M.","given":"M."},{"role":"aut","family":"Buchler","given":"T.","display":"Buchler, T."},{"given":"G.","display":"Niegisch, G.","family":"Niegisch","role":"aut"},{"role":"aut","display":"Goebell, P. J.","given":"P. J.","family":"Goebell"},{"role":"aut","family":"Waddell","display":"Waddell, T.","given":"T."},{"display":"Joly, F.","given":"F.","family":"Joly","role":"aut"},{"family":"Priou","display":"Priou, F.","given":"F.","role":"aut"},{"family":"Retz","given":"M.","display":"Retz, M.","role":"aut"},{"display":"Siemer, S.","given":"S.","family":"Siemer","role":"aut"},{"role":"aut","given":"U.","display":"Zimmermann, U.","family":"Zimmermann"},{"role":"aut","given":"D.","display":"Deckbar, D.","family":"Deckbar"},{"family":"Burkholder","given":"I.","display":"Burkholder, I.","role":"aut"},{"family":"Hartmann","given":"A.","display":"Hartmann, A.","role":"aut"},{"role":"aut","family":"Haanen","given":"J. B.","display":"Haanen, J. B."}],"name":{"displayForm":["L. Bergmann, L. Albiges, M. Ahrens, M. Gross-Goupil, E. Boleti, G. Gravis, A. Fléchon, M.-O. Grimm, J. Bedke, P. Barthélémy, D. Castellano, B. Mellado, P. Ivanyi, S. Rottey, A. Flörcken, C. Suarez, P. Maroto, V. Grünwald, S.F. Oosting, J. Kopecky, S. Zschäbitz, M. Boegemann, T. Buchler, G. Niegisch, P.J. Goebell, T. Waddell, F. Joly, F. Priou, M. Retz, S. Siemer, U. Zimmermann, D. Deckbar, I. Burkholder, A. Hartmann & J.B. Haanen, Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN)"]},"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"July 2025"}],"recId":"1942753071"} 
SRT |a BERGMANNLOPROSPECTIV2025 

Ähnliche Einträge